Skip to main content
. 2022 Sep 27;9:1012220. doi: 10.3389/fcvm.2022.1012220

Figure 2.

Figure 2

Primary endpoint and its individual components in SGLT2-i and non-SGLT2-i users. AF, atrial fibrillation; NOCAs, new-onset cardiac arrhythmias; SGLT2-i, Sodium-glucose co-transporter 2 inhibitors; VF, Ventricular Fibrillation; VT, Ventricular Tachycardia.